Sun Pharmaceutical Industries Limited’s revenue in Q3FY23 rose 14% to ₹ 112,410 millions. Consolidated Profit After Tax came at ₹ 21,808 millions in Q3FY23 showcasing a 3% rise on an YoY basis. In this quarter’s results, the reports suggested that the firm has continued to deliver consistent performance in all key operational and financial indicators in Q3Y23.
